FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3095798169> ?p ?o ?g. }

• W3095798169 endingPage "3230" @default.
• W3095798169 startingPage "3230" @default.
• W3095798169 abstract "Gliomas remain refractory to all attempted treatments, including those using immune checkpoint inhibitors. The characterization of the tumor (immune) microenvironment has been recognized as an important challenge to explain this lack of response and to improve the therapy of glial tumors.We designed a prospective analysis of the immune cells of gliomas by flow cytometry. Tumors with or without isocitrate dehydrogenase 1/2 (IDH1/2) mutations were included in the study. The genetic profile and the presence of different molecular and cellular features of the gliomas were analyzed in parallel. The findings were validated in syngeneic mouse models.We observed that few immune cells infiltrate mutant IDH1/2 gliomas whereas the immune content of IDH1/2 wild-type tumors was more heterogeneous. Some of them contained an important immune infiltrate, particularly enriched in myeloid cells with immunosuppressive features, but others were more similar to mutant IDH1/2 gliomas, with few immune cells and a less immunosuppressive profile. Notably, we observed a direct correlation between the percentage of leukocytes and the presence of vascular alterations, which were associated with a reduced expression of Tau, a microtubule-binding protein that controls the formation of tumor vessels in gliomas. Furthermore, overexpression of Tau was able to reduce the immune content in orthotopic allografts of GL261 cells, delaying tumor growth.We have confirmed the reduced infiltration of immune cells in IDH1/2 mutant gliomas. By contrast, in IDH1/2 wild-type gliomas, we have found a direct correlation between the presence of vascular alterations and the entrance of leukocytes into the tumors. Interestingly, high levels of Tau inversely correlated with the vascular and the immune content of gliomas. Altogether, our results could be exploited for the design of more successful clinical trials with immunomodulatory molecules." @default.
• W3095798169 created "2020-11-09" @default.
• W3095798169 creator A5008990578 @default.
• W3095798169 creator A5009991169 @default.
• W3095798169 creator A5012197993 @default.
• W3095798169 creator A5028696041 @default.
• W3095798169 creator A5039541864 @default.
• W3095798169 creator A5042391554 @default.
• W3095798169 creator A5061698320 @default.
• W3095798169 creator A5065180087 @default.
• W3095798169 creator A5071711554 @default.
• W3095798169 creator A5076482262 @default.
• W3095798169 creator A5077944809 @default.
• W3095798169 creator A5078251623 @default.
• W3095798169 creator A5079799483 @default.
• W3095798169 creator A5084289915 @default.
• W3095798169 date "2020-11-02" @default.
• W3095798169 modified "2023-10-14" @default.
• W3095798169 title "Immune Profiling of Gliomas Reveals a Connection with IDH1/2 Mutations, Tau Function and the Vascular Phenotype" @default.
• W3095798169 cites W1815157104 @default.
• W3095798169 cites W1984650310 @default.
• W3095798169 cites W1988756388 @default.
• W3095798169 cites W2025555160 @default.
• W3095798169 cites W2100795816 @default.
• W3095798169 cites W2116371946 @default.
• W3095798169 cites W2220215167 @default.
• W3095798169 cites W2259413955 @default.
• W3095798169 cites W2326769799 @default.
• W3095798169 cites W2366536035 @default.
• W3095798169 cites W2581747126 @default.
• W3095798169 cites W2596261790 @default.
• W3095798169 cites W2596548837 @default.
• W3095798169 cites W2601414401 @default.
• W3095798169 cites W2603523955 @default.
• W3095798169 cites W2611222875 @default.
• W3095798169 cites W2620446315 @default.
• W3095798169 cites W2764040657 @default.
• W3095798169 cites W2792764803 @default.
• W3095798169 cites W2796207838 @default.
• W3095798169 cites W2801571624 @default.
• W3095798169 cites W2807646229 @default.
• W3095798169 cites W2808732046 @default.
• W3095798169 cites W2864928784 @default.
• W3095798169 cites W2878436114 @default.
• W3095798169 cites W2885505948 @default.
• W3095798169 cites W2911752971 @default.
• W3095798169 cites W2949273159 @default.
• W3095798169 cites W2951880440 @default.
• W3095798169 cites W2969983729 @default.
• W3095798169 cites W2995682532 @default.
• W3095798169 cites W2997058272 @default.
• W3095798169 cites W3002417967 @default.
• W3095798169 cites W3005258006 @default.
• W3095798169 cites W3012490632 @default.
• W3095798169 cites W3030339055 @default.
• W3095798169 cites W3032465961 @default.
• W3095798169 cites W3036982358 @default.
• W3095798169 doi "https://doi.org/10.3390/cancers12113230" @default.
• W3095798169 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7694073" @default.
• W3095798169 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33147752" @default.
• W3095798169 hasPublicationYear "2020" @default.
• W3095798169 type Work @default.
• W3095798169 sameAs 3095798169 @default.
• W3095798169 citedByCount "15" @default.
• W3095798169 countsByYear W30957981692021 @default.
• W3095798169 countsByYear W30957981692022 @default.
• W3095798169 countsByYear W30957981692023 @default.
• W3095798169 crossrefType "journal-article" @default.
• W3095798169 hasAuthorship W3095798169A5008990578 @default.
• W3095798169 hasAuthorship W3095798169A5009991169 @default.
• W3095798169 hasAuthorship W3095798169A5012197993 @default.
• W3095798169 hasAuthorship W3095798169A5028696041 @default.
• W3095798169 hasAuthorship W3095798169A5039541864 @default.
• W3095798169 hasAuthorship W3095798169A5042391554 @default.
• W3095798169 hasAuthorship W3095798169A5061698320 @default.
• W3095798169 hasAuthorship W3095798169A5065180087 @default.
• W3095798169 hasAuthorship W3095798169A5071711554 @default.
• W3095798169 hasAuthorship W3095798169A5076482262 @default.
• W3095798169 hasAuthorship W3095798169A5077944809 @default.
• W3095798169 hasAuthorship W3095798169A5078251623 @default.
• W3095798169 hasAuthorship W3095798169A5079799483 @default.
• W3095798169 hasAuthorship W3095798169A5084289915 @default.
• W3095798169 hasBestOaLocation W30957981691 @default.
• W3095798169 hasConcept C104317684 @default.
• W3095798169 hasConcept C127716648 @default.
• W3095798169 hasConcept C127848430 @default.
• W3095798169 hasConcept C142724271 @default.
• W3095798169 hasConcept C143065580 @default.
• W3095798169 hasConcept C181199279 @default.
• W3095798169 hasConcept C203014093 @default.
• W3095798169 hasConcept C2777150147 @default.
• W3095798169 hasConcept C2778227246 @default.
• W3095798169 hasConcept C502942594 @default.
• W3095798169 hasConcept C55493867 @default.
• W3095798169 hasConcept C71924100 @default.
• W3095798169 hasConcept C86803240 @default.
• W3095798169 hasConcept C8891405 @default.
• W3095798169 hasConceptScore W3095798169C104317684 @default.

• next